Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

Abstract

One dose or two? For two-dose vaccines against severe acute respiratory syndrome coronavirus 2, some jurisdictions have decided to delay the second dose to rapidly get the vaccine into more people. The consequences of deviating from manufacturer-prescribed dosing regimens are unknown but will depend on the strength of immune responses to the vaccines. Saad-Roy et al. took a modeling approach to tackling the inevitable uncertainties facing vaccine rollout. The authors found that although one-dose strategies generally reduce infections in the short term, in the long term, the outcome depends on immune robustness. A one-dose strategy may increase the potential for antigenic evolution if immune responses are suboptimal and the virus continues to replicate in some vaccinated people, potentially leading to immune-escape mutations. It is critical to gather serological data from vaccinated people and, to avoid negative outcomes, to ramp up vaccination efforts worldwide. Science , this issue p. 363

Cited by papers we hold 5

• The changing epidemiology of SARS-CoV-2 · 2022
  No notice
• Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination · 2021
  No notice
• Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom · 2021
  No notice
• Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom · 2021
  No notice
• Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.